These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Absence of specific binding of several putative neuro-transmitters to human fibroblasts. Berrettini WH; Nadi NS; Gershon ES J Recept Res; 1983; 3(3):409-21. PubMed ID: 6137566 [TBL] [Abstract][Full Text] [Related]
43. Clinical strategies for evaluating ECT mechanisms--pharmacological, biochemical and psychophysiological approaches. Lerer B; Sitaram N Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):309-33. PubMed ID: 6137030 [TBL] [Abstract][Full Text] [Related]
45. A Markov process based model of the neurotransmitter-receptor binding process in the brain--comment. Farooqi ZH Drug Des Deliv; 1989 May; 4(3):257-9. PubMed ID: 2577442 [No Abstract] [Full Text] [Related]
46. The labelling and isolation of neuroreceptors. Fewtrell CM Neuroscience; 1976 Aug; 1(4):249-73. PubMed ID: 11370512 [No Abstract] [Full Text] [Related]
47. GABAA receptors and opioid receptors as examples of multiple site receptor proteins. Barnard E Alcohol Drug Res; 1985-1986; 6(2-3):63-5. PubMed ID: 2868734 [No Abstract] [Full Text] [Related]
48. Alterations in neurotransmitter activity after acute and chronic ethanol treatment: studies of transmitter interactions. Hunt WA; Majchrowicz E; Dalton TK; Swartzwelder HS; Wixon H Alcohol Clin Exp Res; 1979 Oct; 3(4):359-63. PubMed ID: 42321 [TBL] [Abstract][Full Text] [Related]
49. Architectonics of the human cerebral cortex and transmitter receptor fingerprints: reconciling functional neuroanatomy and neurochemistry. Zilles K; Palomero-Gallagher N; Grefkes C; Scheperjans F; Boy C; Amunts K; Schleicher A Eur Neuropsychopharmacol; 2002 Dec; 12(6):587-99. PubMed ID: 12468022 [TBL] [Abstract][Full Text] [Related]
50. The fluctuating Parkinsonian patient--clinical and pathophysiological aspects. Blanchet PJ Can J Neurol Sci; 2003 Mar; 30 Suppl 1():S19-26. PubMed ID: 12691473 [TBL] [Abstract][Full Text] [Related]
52. [Usefulness of positron-emission tomography in the study of the central nervous system]. Arquè Bertrán JM; Frost JJ Med Clin (Barc); 1990 Apr; 94(16):633-6. PubMed ID: 1974314 [No Abstract] [Full Text] [Related]
54. Neurochemical and neuroreceptor imaging with PET in Parkinson's disease. Stoessl AJ Adv Neurol; 2001; 86():215-23. PubMed ID: 11553980 [No Abstract] [Full Text] [Related]
55. Autoreceptors in the central nervous system. Timmermans PB; Thoolen MJ Med Res Rev; 1987; 7(3):307-32. PubMed ID: 3041133 [No Abstract] [Full Text] [Related]
56. Basic research strategies for imaging neurotransmitter systems. Snyder SH NIDA Res Monogr; 1986; 74():6-14. PubMed ID: 2892136 [No Abstract] [Full Text] [Related]
57. Drug addiction and brain targets: from preclinical research to pharmacotherapy. Rahman S CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):391-2. PubMed ID: 19128198 [No Abstract] [Full Text] [Related]
58. Neurotransmitter receptors on microglia. Liu H; Leak RK; Hu X Stroke Vasc Neurol; 2016 Jun; 1(2):52-58. PubMed ID: 28959464 [TBL] [Abstract][Full Text] [Related]
59. Commentary on "The current status of PET scanning with respect to schizophrenia". Buchsbaum MS Neuropsychopharmacology; 1992 Aug; 7(1):67-8; discussion 73-5. PubMed ID: 1355970 [No Abstract] [Full Text] [Related]
60. Involvement of transmitter systems in neuropsychiatric diseases. Hartmann J; Künig G; Riederer P Acta Neurol Scand Suppl; 1993; 146():18-21. PubMed ID: 8101412 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]